These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25543485)

  • 1. [Clinical efficacy of idarubicin combined with methotrexate for treatment of patients with central nervous system diffuse large B cell lymphoma].
    Yuan P; Yu ZP; Yue TH; Xiao YH; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1621-3. PubMed ID: 25543485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
    Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
    Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
    Maciocia P; Badat M; Cheesman S; D'Sa S; Joshi R; Lambert J; Mohamedbhai S; Pule M; Linch D; Ardeshna K
    Br J Haematol; 2016 Feb; 172(4):545-53. PubMed ID: 26684148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
    Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
    J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System].
    Okamoto S; Tanaka M; Goto T; Nakashima M; Nagura E
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2109-2112. PubMed ID: 29361628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin).
    Bertini M; Freilone R; Botto B; Calvi R; Gallamini A; Gatti AM; Liberati AM; Meneghini V; Orlandi E; Orsucci L; Pizzuti M; Rota Scalabrini D; Salvi F; Todeschini G; Vitolo U; Resegotti L
    Haematologica; 1997; 82(3):309-13. PubMed ID: 9234577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study.
    Miwa A; Sekiguchi N; Tanimura A; Homma C; Shikai T; Takezako Y; Yamagata N; Takezako N
    Leuk Lymphoma; 2011 Oct; 52(10):1898-903. PubMed ID: 21649542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Rare Case of Spontaneous Remission and Relapse of a Primary Central Nervous System Lymphoma.
    Ramos R; Fernandes JS; Almeida M; Almeida R
    Acta Med Port; 2018 Dec; 31(12):777-783. PubMed ID: 30684376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
    Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
    J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen.
    Moreton P; Morgan GJ; Gilson D; Smith GM; McVerry BA; Davies JM; Mackie MJ; Bolam S; Jalihal SS; Howard MR; Parapia LA; Williams AT; Child JA;
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):324-8. PubMed ID: 14704830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab.
    Liu CY; Teng HW; Lirng JF; Chiou TJ; Chen PM; Hsiao LT
    Leuk Lymphoma; 2008 Oct; 49(10):2018-21. PubMed ID: 18728965
    [No Abstract]   [Full Text] [Related]  

  • 19. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
    Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
    Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.